Ezt az oldalt automatikusan lefordították, és a fordítás pontossága nem garantált. Kérjük, olvassa el a angol verzió forrásszöveghez.

A Study to Evaluate S241656 Alone or in Combination in Participants With Selected Myeloid Malignancies

2026. július 17. frissítette: Servier

A Phase 1/2, Open Label, Multicenter, Multi-cohort Study of S241656 as Monotherapy or in Combination With Other Antileukemic Agents in Participants With Selected Myeloid Malignancies

The objective of this study is to evaluate the safety, tolerability, and pharmacokinetics (PK) of S241656 and to determine the recommended dose for expansion (RDE) of S241656 in participants with relapsed/refractory (R/R) acute myeloid leukemia (AML), myelodysplastic syndrome/acute myeloid leukemia (MDS/AML), or chronic myelomonocytic leukemia (CMML). Part 1A dose escalation will determine the RDE to be used in a future expansion stage of the trial. An optional Part 1B drug-drug interaction (DDI) substudy will evaluate the effect of posaconazole on the PK of S241656.

The study consists of a screening period of up to 21 days, a treatment period consisting of continuous 28-day cycles of treatment, an end-of-treatment visit, a safety follow-up period, and long-term disease and survival follow-up every 3 months. Participants in the optional DDI substudy may continue treatment in the main study following completion of the DDI assessment period. Participants may undergo bone marrow aspirates and/or biopsies, blood tests, electrocardiograms (ECGs), echocardiograms or multigated acquisition (MUGA) scans, physical examinations, ophthalmologic assessments, and disease response questionnaires.

A tanulmány áttekintése

Tanulmány típusa

Beavatkozó

Beiratkozás (Becsült)

64

Fázis

  • 2. fázis
  • 1. fázis

Kapcsolatok és helyek

Ez a rész a vizsgálatot végzők elérhetőségeit, valamint a vizsgálat lefolytatásának helyére vonatkozó információkat tartalmazza.

Tanulmányi kapcsolat

Részvételi kritériumok

A kutatók olyan embereket keresnek, akik megfelelnek egy bizonyos leírásnak, az úgynevezett jogosultsági kritériumoknak. Néhány példa ezekre a kritériumokra a személy általános egészségi állapota vagy a korábbi kezelések.

Jogosultsági kritériumok

Tanulmányozható életkorok

  • Felnőtt
  • Idősebb felnőtt

Egészséges önkénteseket fogad

Nem

Leírás

Inclusion Criteria:

  • Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 2.
  • Investigator-assessed life expectancy of ≥ 3 months.
  • Able and willing to comply with requirements of the study protocol.
  • Documented genetic characterization of the disease as per local practice.
  • Clinical and laboratory thresholds:
  • Cytoreduction: white blood cell (WBC) < 25 × 10⁹/L (hydroxyurea/cytarabine/leukapheresis allowed).
  • Renal: creatinine clearance (CrCl) ≥ 60 mL/min (Cockcroft-Gault).
  • Hepatic: aspartate aminotransferase (AST)/alanine aminotransferase (ALT) ≤ 3 × upper limit of normal (ULN) (5 × if leukemic); Total bilirubin ≤ 1.5 × ULN (≤ 3 × ULN for Gilbert's syndrome).
  • Part 1 Only: Relapsed/Refractory (R/R), pathologically confirmed AML, MDS/AML, or CMML.
  • Part 1 Only: Must have failed ≥ 1 approved standard therapy and have no other approved standard options.

Exclusion Criteria:

  • Known hypersensitivity to S241656, or Posaconazole (Part 1B).
  • Pregnant or breastfeeding; positive serum pregnancy test for WOCBP.
  • Diagnosis of acute promyelocytic leukemia (French-American-British [FAB] M3 classification), MPN, mixed/ambiguous lineage, histiocytic/dendritic cell neoplasms, or AML with isolated extramedullary disease (no marrow/blood involvement).
  • Active Central Nervous System (CNS) disease (by cytologic or radiographic evidence).
  • Failure to recover to ≤ Grade 1 from previous toxicities (except Grade 2 neuropathy/alopecia).
  • Major surgery within 4 weeks.
  • Any anticancer therapy within 2 weeks or 5 half-lives (28 days for biologics). Cytoreduction with hydroxyurea or cytarabine is permitted.
  • Prior use of experimental KRAS/BRAF/MEK/ERK inhibitors (prior FLT3 inhibitors are permitted).
  • Uncontrolled infections (human immunodeficiency virus (HIV)/hepatitis B virus (HBV)/hepatitis C virus (HCV) permitted only if viral load is undetectable/controlled and specific cluster of differentiation 4 (CD4)+ criteria are met).
  • Malabsorption, Crohn's, or chronic vomiting that impacts oral drug absorption.
  • History/risk of retinal vein occlusion (RVO), glaucoma, or hyper-viscosity syndromes.
  • Other active malignancy requiring systemic therapy within 2 years (except non-melanoma skin cancer or localized/cured tumors).
  • Stroke, myocardial infarction (MI), unstable angina, or acute coronary syndrome within 6 months.
  • Congestive heart failure (CHF), clinically significant cardiac arrhythmias according to the investigator's judgement (e.g., ventricular tachycardia), complete left bundle branch block and high-grade atrioventricular (AV) block (e.g., bifascicular block, Mobitz type II- and third degree AV block).
  • Fridericia-corrected QT interval (QTcF) > 470 msec or history of Torsades de pointes.
  • Disseminated intravascular coagulation (DIC), significant coagulopathy according to the investigator's judgement, or uncontrolled bleeding.
  • Proton Pump Inhibitors (PPIs) and potassium-competitive acid blockers ≥ 7 days prior to Cycle 1 Day 1.
  • Breast cancer resistance protein (BCRP) sensitive substrate or with a narrow therapeutic index (NTI)
  • All herbal preparations/supplements are prohibited.

Tanulási terv

Ez a rész a vizsgálati terv részleteit tartalmazza, beleértve a vizsgálat megtervezését és a vizsgálat mérését.

Hogyan készül a tanulmány?

Tervezési részletek

  • Elsődleges cél: Kezelés
  • Kiosztás: Nem véletlenszerű
  • Beavatkozó modell: Szekvenciális hozzárendelés
  • Maszkolás: Nincs (Open Label)

Fegyverek és beavatkozások

Résztvevő csoport / kar
Beavatkozás / kezelés
Kísérleti: Part 1A: Dose Escalation
Tablets taken by mouth.
Kísérleti: Part 1B: Optional Drug-Drug Interaction [DDI] Substudy
Tablets taken by mouth.
Tablets taken by mouth

Mit mér a tanulmány?

Elsődleges eredményintézkedések

Eredménymérő
Időkeret
(Part 1A and 1B) Dose limiting toxicity (DLTs) associated with S241656 during the first cycle of treatment
Időkeret: Through Cycle 1 (28 days)
Through Cycle 1 (28 days)
(Part 1A and 1B) Number of Adverse Events (AEs)
Időkeret: Through 30 days after the last dose of treatment, up to approximately 4 years
Through 30 days after the last dose of treatment, up to approximately 4 years
(Part 1A and 1B) Number of Serious Adverse Events (SAEs)
Időkeret: Through 30 days after the last dose of treatment, up to approximately 4 years
Through 30 days after the last dose of treatment, up to approximately 4 years
(Part 1A and 1B) Severity of AEs
Időkeret: Through 30 days after the last dose of treatment, up to approximately 4 years
Through 30 days after the last dose of treatment, up to approximately 4 years
(Part 1A and 1B) Severity of SAEs
Időkeret: Through 30 days after the last dose of treatment, up to approximately 4 years
Through 30 days after the last dose of treatment, up to approximately 4 years
(Part 1A and 1B) Duration of AEs
Időkeret: Through 30 days after the last dose of treatment, up to approximately 4 years
Through 30 days after the last dose of treatment, up to approximately 4 years
(Part 1A and 1B) Duration of SAEs
Időkeret: Through 30 days after the last dose of treatment, up to approximately 4 years
Through 30 days after the last dose of treatment, up to approximately 4 years
(Part 1A and 1B) Number of changes in safety laboratory results
Időkeret: Through 30 days after the last dose of treatment, up to approximately 4 years
Through 30 days after the last dose of treatment, up to approximately 4 years
(Part 1A and 1B) Number of changes in physical examination
Időkeret: Through 30 days after the last dose of treatment, up to approximately 4 years
Through 30 days after the last dose of treatment, up to approximately 4 years
(Part 1A and 1B) Number of dose reductions due to AEs
Időkeret: Through end of treatment, up to approximately 4 years
Through end of treatment, up to approximately 4 years
(Part 1A and 1B) Number of dose interruptions due to AEs
Időkeret: Through end of treatment, up to approximately 4 years
Through end of treatment, up to approximately 4 years
(Part 1A and 1B) Number of dose delays due to AEs
Időkeret: Through end of treatment, up to approximately 4 years
Through end of treatment, up to approximately 4 years
(Part 1A and 1B) Number of study withdrawals due to AEs
Időkeret: Through end of treatment, up to approximately 4 years
Through end of treatment, up to approximately 4 years
(Part 1B only) Maximum concentration (Cmax) of S241656
Időkeret: Through Cycle 1 (28 days)
Through Cycle 1 (28 days)
(Part 1B only) Cmax of metabolite S243796
Időkeret: Through Cycle 1 (28 days)
Through Cycle 1 (28 days)
(Part 1B only) Time corresponding to Cmax (Tmax) of S241656
Időkeret: Through Cycle 1 (28 days)
Through Cycle 1 (28 days)
(Part 1B only) Tmax of metabolite S243796
Időkeret: Through Cycle 1 (28 days)
Through Cycle 1 (28 days)
(Part 1B only) Terminal half-life (t1/2) of S241656
Időkeret: Through Cycle 1 (28 days)
Through Cycle 1 (28 days)
(Part 1B only) t1/2 of metabolite S243796
Időkeret: Through Cycle 1 (28 days)
Through Cycle 1 (28 days)
(Part 1B only) Area under the curve (AUC) of S241656
Időkeret: Through Cycle 1 (28 days)
Through Cycle 1 (28 days)
(Part 1B only) AUC of metabolite S243796
Időkeret: Through Cycle 1 (28 days)
Through Cycle 1 (28 days)

Másodlagos eredményintézkedések

Eredménymérő
Intézkedés leírása
Időkeret
(Part 1A only) Cmax of S241656
Időkeret: Through end of treatment, up to approximately 4 years
Through end of treatment, up to approximately 4 years
(Part 1A only) Cmax of metabolite S243796
Időkeret: Through end of treatment, up to approximately 4 years
Through end of treatment, up to approximately 4 years
(Part 1A only) Tmax of S241656
Időkeret: Through end of treatment, up to approximately 4 years
Through end of treatment, up to approximately 4 years
(Part 1A only) Tmax of metabolite S243796
Időkeret: Through end of treatment, up to approximately 4 years
Through end of treatment, up to approximately 4 years
(Part 1A only) AUC of S241656
Időkeret: Through end of treatment, up to approximately 4 years
Through end of treatment, up to approximately 4 years
(Part 1A only) AUC of metabolite S243796
Időkeret: Through end of treatment, up to approximately 4 years
Through end of treatment, up to approximately 4 years
(Part 1A only) t1/2 of S241656
Időkeret: Through end of treatment, up to approximately 4 years
Through end of treatment, up to approximately 4 years
(Part 1A only) t1/2 of metabolite S243796
Időkeret: Through end of treatment, up to approximately 4 years
Through end of treatment, up to approximately 4 years
(Part 1A and 1B) Complete remission (CR)
Időkeret: Through study completion, approximately 4 years
Through study completion, approximately 4 years
(Part 1A and 1B) Complete remission with incomplete hematologic recovery (CRi)
Időkeret: Through study completion, approximately 4 years
In participants with AML or MDS/AML only
Through study completion, approximately 4 years
(Part 1A and 1B) Morphologic leukemia free state (MLFS)
Időkeret: Through study completion, approximately 4 years
In participants with AML or MDS/AML only
Through study completion, approximately 4 years
(Part 1A and 1B) Complete remission with partial hematologic recovery (CRh)
Időkeret: Through study completion, approximately 4 years
In participants with AML or MDS/AML only
Through study completion, approximately 4 years
(Part 1A and 1B) Partial response (PR)
Időkeret: Through study completion, approximately 4 years
Through study completion, approximately 4 years
(Part 1A and 1B) Objective response (OR)
Időkeret: Through study completion, approximately 4 years
Through study completion, approximately 4 years
(Part 1A and 1B) Composite complete remission (CRc)
Időkeret: Through study completion, approximately 4 years
In participants with AML or MDS/AML only
Through study completion, approximately 4 years
(Part 1A and 1B) Red blood cell (RBC) and platelet transfusion independence for at least 8 weeks
Időkeret: Through end of treatment, up to approximately 4 years
In participants with AML or MDS/AML only
Through end of treatment, up to approximately 4 years
(Part 1A and 1B) Duration of response (DOR)
Időkeret: Through study completion, approximately 4 years
Through study completion, approximately 4 years
(Part 1A and 1B) Time to response (TTR)
Időkeret: Through study completion, approximately 4 years
In participants with AML or MDS/AML only
Through study completion, approximately 4 years
(Part 1A and 1B) Event free survival (EFS)
Időkeret: Through study completion, approximately 4 years
In participants with AML or MDS/AML only
Through study completion, approximately 4 years
(Part 1A and 1B) Overall survival (OS)
Időkeret: Through study completion, approximately 4 years
Through study completion, approximately 4 years
(Part 1A and 1B) Marrow response
Időkeret: Through end of treatment, up to approximately 4 years
In participants with CMML only
Through end of treatment, up to approximately 4 years
(Part 1A and 1B) Number of participants with erythroid-, neutrophil-, platelet or spleen-response
Időkeret: Through end of treatment, up to approximately 4 years
In participants with CMML only
Through end of treatment, up to approximately 4 years

Együttműködők és nyomozók

Itt találhatja meg a tanulmányban érintett személyeket és szervezeteket.

Szponzor

Tanulmányi rekorddátumok

Ezek a dátumok nyomon követik a ClinicalTrials.gov webhelyre benyújtott vizsgálati rekordok és összefoglaló eredmények benyújtásának folyamatát. A vizsgálati feljegyzéseket és a jelentett eredményeket a Nemzeti Orvostudományi Könyvtár (NLM) felülvizsgálja, hogy megbizonyosodjon arról, hogy megfelelnek-e az adott minőség-ellenőrzési szabványoknak, mielőtt közzéteszik őket a nyilvános weboldalon.

Tanulmány főbb dátumok

Tanulmány kezdete (Becsült)

2026. szeptember 15.

Elsődleges befejezés (Becsült)

2027. november 1.

A tanulmány befejezése (Becsült)

2030. szeptember 30.

Tanulmányi regisztráció dátumai

Először benyújtva

2026. július 8.

Először nyújtották be, amely megfelel a minőségbiztosítási kritériumoknak

2026. július 17.

Első közzététel (Tényleges)

2026. július 22.

Tanulmányi rekordok frissítései

Utolsó frissítés közzétéve (Tényleges)

2026. július 22.

Az utolsó frissítés elküldve, amely megfelel a minőségbiztosítási kritériumoknak

2026. július 17.

Utolsó ellenőrzés

2026. július 1.

Több információ

A tanulmányhoz kapcsolódó kifejezések

Terv az egyéni résztvevői adatokhoz (IPD)

Tervezi megosztani az egyéni résztvevői adatokat (IPD)?

IGEN

IPD terv leírása

Qualified scientific and medical researchers can request access to anonymized patient-level and study-level clinical trial data.

Access can be requested for all interventional clinical studies:

  • used for Marketing Authorization (MA) of medicines and new indications approved after 1 January 2014 in the European Economic Area (EEA) or the United States (US).
  • where Servier is the Marketing Authorization Holder (MAH). The date of the first MA of the new medicine (or the new indication) in one of the EEA Member States will be considered for this scope.

In addition, access can be requested for all interventional clinical studies in patients:

  • sponsored by Servier
  • with a first patient enrolled as of 1 January 2004 onwards
  • for New Chemical Entity or New Biological Entity (new pharmaceutical form excluded) for which development has been terminated before any Marketing authorization (MA) approval.

IPD megosztási időkeret

After Marketing Authorization in EEA or US if the study is used for the approval.

IPD-megosztási hozzáférési feltételek

Researchers should register on Servier Data Portal and fill in the research proposal form. This form in four parts should be fully documented. The Research Proposal Form will not be reviewed until all mandatory fields are completed.

Az IPD megosztását támogató információ típusa

  • STUDY_PROTOCOL
  • NEDV
  • ICF
  • CSR

Gyógyszer- és eszközinformációk, tanulmányi dokumentumok

Egy amerikai FDA által szabályozott gyógyszerkészítményt tanulmányoz

Igen

Egy amerikai FDA által szabályozott eszközterméket tanulmányoz

Nem

Ezt az információt közvetlenül a clinicaltrials.gov webhelyről szereztük be, változtatás nélkül. Ha bármilyen kérése van vizsgálati adatainak módosítására, eltávolítására vagy frissítésére, kérjük, írjon a következő címre: register@clinicaltrials.gov. Amint a változás bevezetésre kerül a clinicaltrials.gov oldalon, ez a webhelyünkön is automatikusan frissül. .

Iratkozz fel